Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer
The poster presentation relates to data demonstrating the significant synergistic anti-cancer effects of GEN-1 in combination with Avastin® and Doxil®, as well as promising safety and efficacy clinical data for GEN-1 in combination with Doxil® in platinum-resistant ovarian cancer patients.
Details of the presentation are as follows:
Abstract Title: Interleukin-12 Gene Therapy in Combination with Bevacizumab and PEGylated Liposomal Doxorubin for Treatment of Disseminated Ovarian Cancer
Session Title: Drug Delivery
Date and Time:
"GEN-1 has consistently shown improved outcomes in both pre-clinical and clinical studies when combined with standard of care therapeutics," said
The Company is currently enrolling patients in the OVATION Study, a Phase 1b dose escalating trial combining GEN-1 with neo-adjuvant therapies in newly diagnosed ovarian cancer patients which will provide a starting dose for a follow-on Phase 1/2 study combining GEN-1 with Avastin® and Doxil®. The Phase 1/2 combination trial is expected to begin in the second half of 2016.
About GEN-1 Immunotherapy
GEN-1, designed using Celsion's proprietary TheraPlas™ platform technology, is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anti-cancer immunity acting through the induction of T-lymphocyte and natural killer (NK) cell proliferation. The Company has previously reported positive safety and encouraging Phase I results with GEN-1 given as monotherapy in patients with peritoneally metastasized ovarian cancer, and recently completed a Phase Ib trial of GEN-1 in combination with PEGylated doxorubicin in patients with platinum-resistant ovarian cancer. GEN-1 has also demonstrated preclinical activity in glioblastoma multiforme (brain cancer) and the Company plans to initiate a Phase I study in this indication in the second half of 2015.
About
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™ and TheraSilence™. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-G1) (CLSN-OV)
Celsion Investor Contact
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
Celsion Media Contacts
Harriet Shelare
Director, Communications
860-483-1721
hshelare@celsion.com
Bill Berry
Berry & Company
212-253-8881
bberry@berrypr.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/celsion-announces-upcoming-presentation-at-aacr-2016-highlighting-potential-of-gen-1-il-12-immunotherapy-in-ovarian-cancer-300249446.html
SOURCE
News Provided by Acquire Media